AstraZeneca said its Fasenra treatment for a rare inflammatory disease of the oesophagus failed to meet one of the two dual-primary endpoints in a phase 3 trial.
Fasenra demonstrated a statistically significant improvement in histological disease remission, but not a change in dysphagia symptoms, compared to placebo, in patients with Eosinophilic oesophagitis (EoE) aged 12 or older.
EoE is a rare, progressive, chronic inflammatory disease of the oesophagus currently believed to be characterised by the abnormal presence of eosinophils, a type of white blood cell, in the inner lining of the esophagus. Patients experience difficulty with swallowing (dysphagia), pain, food getting stuck and anxiety.
Reporting by Frank Prenesti for Sharecast.com
